{"id":939395,"date":"2026-02-24T08:26:31","date_gmt":"2026-02-24T13:26:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/"},"modified":"2026-02-24T08:26:31","modified_gmt":"2026-02-24T13:26:31","slug":"bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/","title":{"rendered":"Bolt Biotherapeutics to Participate in Upcoming March Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>REDWOOD CITY, Calif., Feb.  24, 2026  (GLOBE NEWSWIRE) &#8212; Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>TD Cowen 46th Annual Health Care Conference<\/strong><br \/>\n          <br \/>Company presentation on Monday, March 2, 2026 at 9:50 a.m. EST (6:50 a.m. PST)<\/li>\n<li>\n          <strong>Leerink Partners Global Healthcare Conference<\/strong><br \/>\n          <br \/>Participating in 1&#215;1 meetings on Wednesday, March 11, 2026<\/li>\n<\/ul>\n<p>\n        <strong>About Bolt Biotherapeutics, Inc.<\/strong><br \/>\n        <br \/>The mission of Bolt Biotherapeutics is to harness the power of the immune system to improve lives and eradicate cancer. The Company is developing BDC-4182, a next-generation Boltbody\u2122 Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-4182 is currently in a Phase 1 dose escalation trial that includes patients with gastric and gastroesophageal cancer. The Company has strategic collaborations with Genmab and Toray built around the Company\u2019s Boltbody\u2122 Immune-Stimulating Antibody Conjugate (ISAC) platform technology and its expertise in myeloid biology. The Company is seeking to partner BDC-3042, a Dectin-2 agonist that recently completed a first-in-human Phase 1 dose escalation trial, as well as its preclinical ISAC programs targeting CEA and PD-L1. <br \/>For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d0PivfGJ_OqXDUiBwnJpjc0txh9dvz_nQCqk74TKApBeQ8X0U90VwAiT_5UisJ0BBOmjwYC6QNBDMPWmhi6igUL70G3TejabZzh1UYoUEek=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.boltbio.com\/<\/a>.<\/p>\n<p>\n        <strong>Investor Relations and Media Contact:<\/strong><br \/>\n        <br \/>Matthew DeYoung <br \/>Argot Partners<br \/>(212) 600-1902<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yP2t5E0Dwd8v6xuXbMghRdBCjpFJfRbXOedD3Tm2vUR0C4xF1spth2bxYMzqJd5CUYJ7Ze6GuYpBpbUAXGl-Ec47snphLiwkSrHt9xIbKHeF-secGzrOG0mItxoLxMGALPk5ILRWuil74pDYKN1HYUurv9k8p7inNmYI6DQB9KHHcyF8HSBJmg-PebJsJTKSKqYhrEqdEiStMez7pxOwzlb7B1YPAEMwGZLL87eAclDd9hkTN_xZwdPJPtAWH88ZmFBJlnMZvH57rjQg3Vhy5ESh2UyL7iu2jEkZwDkG-TE=\" rel=\"nofollow\" target=\"_blank\">boltbio@argotpartners.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTcwOCM3NDUwNTE1IzIyMDE4ODk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDFkODUyNDQtZTE1OC00Njg4LTg5YzUtMGM1ZmRlNjQ2MzRiLTEyMTM0NDItMjAyNi0wMi0yNC1lbg==\/tiny\/Bolt-Biotherapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) &#8212; Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March: TD Cowen 46th Annual Health Care Conference Company presentation on Monday, March 2, 2026 at 9:50 a.m. EST (6:50 a.m. PST) Leerink Partners Global Healthcare Conference Participating in 1&#215;1 meetings on Wednesday, March 11, 2026 About Bolt Biotherapeutics, Inc. The mission of Bolt Biotherapeutics is to harness the power of the immune system to improve lives and eradicate cancer. The Company is developing BDC-4182, a next-generation Boltbody\u2122 Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-4182 is currently in a Phase 1 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bolt Biotherapeutics to Participate in Upcoming March Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-939395","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bolt Biotherapeutics to Participate in Upcoming March Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bolt Biotherapeutics to Participate in Upcoming March Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) &#8212; Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March: TD Cowen 46th Annual Health Care Conference Company presentation on Monday, March 2, 2026 at 9:50 a.m. EST (6:50 a.m. PST) Leerink Partners Global Healthcare Conference Participating in 1&#215;1 meetings on Wednesday, March 11, 2026 About Bolt Biotherapeutics, Inc. The mission of Bolt Biotherapeutics is to harness the power of the immune system to improve lives and eradicate cancer. The Company is developing BDC-4182, a next-generation Boltbody\u2122 Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-4182 is currently in a Phase 1 &hellip; Continue reading &quot;Bolt Biotherapeutics to Participate in Upcoming March Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T13:26:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTcwOCM3NDUwNTE1IzIyMDE4ODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bolt Biotherapeutics to Participate in Upcoming March Conferences\",\"datePublished\":\"2026-02-24T13:26:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\\\/\"},\"wordCount\":210,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1OTcwOCM3NDUwNTE1IzIyMDE4ODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\\\/\",\"name\":\"Bolt Biotherapeutics to Participate in Upcoming March Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1OTcwOCM3NDUwNTE1IzIyMDE4ODk=\",\"datePublished\":\"2026-02-24T13:26:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1OTcwOCM3NDUwNTE1IzIyMDE4ODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1OTcwOCM3NDUwNTE1IzIyMDE4ODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bolt Biotherapeutics to Participate in Upcoming March Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bolt Biotherapeutics to Participate in Upcoming March Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Bolt Biotherapeutics to Participate in Upcoming March Conferences - Market Newsdesk","og_description":"REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) &#8212; Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March: TD Cowen 46th Annual Health Care Conference Company presentation on Monday, March 2, 2026 at 9:50 a.m. EST (6:50 a.m. PST) Leerink Partners Global Healthcare Conference Participating in 1&#215;1 meetings on Wednesday, March 11, 2026 About Bolt Biotherapeutics, Inc. The mission of Bolt Biotherapeutics is to harness the power of the immune system to improve lives and eradicate cancer. The Company is developing BDC-4182, a next-generation Boltbody\u2122 Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-4182 is currently in a Phase 1 &hellip; Continue reading \"Bolt Biotherapeutics to Participate in Upcoming March Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-24T13:26:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTcwOCM3NDUwNTE1IzIyMDE4ODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bolt Biotherapeutics to Participate in Upcoming March Conferences","datePublished":"2026-02-24T13:26:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/"},"wordCount":210,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTcwOCM3NDUwNTE1IzIyMDE4ODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/","name":"Bolt Biotherapeutics to Participate in Upcoming March Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTcwOCM3NDUwNTE1IzIyMDE4ODk=","datePublished":"2026-02-24T13:26:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTcwOCM3NDUwNTE1IzIyMDE4ODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTcwOCM3NDUwNTE1IzIyMDE4ODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bolt Biotherapeutics to Participate in Upcoming March Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/939395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=939395"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/939395\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=939395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=939395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=939395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}